Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome’s Promising Outlook: Buy Rating Affirmed on Varegacestat’s Phase 3 Success and Strong Management
- Immunome price target raised to $40 from $38 at Leerink
- Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
- Here’s Why Immunome Stock (IMNM) Soared Over 20% Today
- Immunome’s Varegacestat Shines in Phase 3 RINGSIDE Trial, Earning Buy Rating from Charles Zhu